Abstract
Get full access to this article
View all access options for this article.
References
1.De novo design of epitope-specific antibodies against soluble and multipass membrane proteins with high specificity, developability, and function . Nabla Bio ; 2024 . Available from: https://nabla-public.s3.us-east-1.amazonaws.com/2024_Nabla_JAM_de_novo_antibodies.pdf [Last accessed: May 13 , 25
2.De novo design of hundreds of functional GPCR-targeting antibodies enabled by scaling test-time compute . Nabla Bio ; 2025 . Available from: https://nabla-public.s3.us-east-1.amazonaws.com/2025_nabla_de_novo_antibodies_gpcrs.pdf [Last accessed: May 13 , 25
3.
Bennett
NR
,
Watson
JL
,
Ragotte
RJ
et al. Atomically accurate de novo design of antibodies with RFdiffusion . bioRxiv , 2025 ; doi: 10.1101/2024.03.14.585103.
4.
Trang
B
. Two biotechs say they’re using AI to conjure drugs from scratch. Their documents suggest otherwise . STAT ; 2025 . Available from: https://www.statnews.com/2025/02/10/ai-drug-development-claims-by-biotech-companies-absci-generate-biomedicines-questioned/ [Last accessed: May 13 , 25
5.
Shanehsazzadeh
A
,
McPartlon
M
,
Kasun
G
et al. Unlocking de novo antibody design with generative artificial intelligence . bioRxiv , 2024 ; doi: 10.1101/2023.01.08.523187
6.Absci First to Create and Validate De Novo Antibodies with Zero-Shot Generative AI . Absci ; 2023 . Available from: https://investors.absci.com/news-releases/news-release-details/absci-first-create-and-validate-de-novo-antibodies-zero-shot [Last accessed: May 13 , 25
7.Absci Highlights Progress and Updates Across Proprietary Pipeline and Leading AI Platform at 2024 R&D Day . Absci ; 2024 . Available from: https://investors.absci.com/news-releases/news-release-details/absci-highlights-progress-and-updates-across-proprietary [Last accessed: May 13 , 25
8.
Marden
GC
,
Schmitt
KP
,
Zimmerman
MI
et al. Functional and structural characterization of a combination of pan-sarbecovirus antibodies with potent antiviral activity . bioRxiv , 2025 ; doi: 10.1101/2025.03.30.646023.
9.
Ingraham
JB
,
Baranov
M
,
Costello
Z
et al. Illuminating protein space with a programmable generative model . Nature , 2023 ; 623 (7989 ):1070 –1078 ; doi: 10.1038/s41586-023-06728-8
10.
Lin
F
. New Generative AI Model Designs Proteins Not Found in Nature . Genetic Engineering & Biotechnology News ; 2023 . Available from: https://www.genengnews.com/topics/artificial-intelligence/new-generative-ai-model-designs-proteins-not-found-in-nature/ [Last accessed: May 13 , 25
11.
Philippidis
A
. Genetic Engineering & Biotechnology News. Novartis, Generate:Biomedicines Sign Up-to-$1B AI Protein Drug Collaboration . 2024 . Available from: https://www.genengnews.com/topics/artificial-intelligence/novartis-generatebiomedicines-sign-up-to-1b-ai-protein-drug-collaboration/ [Last accessed: May 13 , 25
12.
Shanker
VR
,
Bruun
TUJ
,
Hie
BL
et al. Unsupervised evolution of protein and antibody complexes with a structure-informed language model . Science , 2024 ; 385 (6704 ):46 –53 ; doi: 10.1126/science.adk8946
13.
Jiang
K
,
Yan
Z
,
Di Bernardo
M
et al. Rapid in silico directed evolution by a protein language model with EVOLVEpro . Science , 2025 ; 387 (6732 ):eadr6006 ; doi: 10.1126/science.adr6006
14.Machine learning-guided generation of a potent combination of broadly neutralizing sarbecovirus antibodies with a high barrier to resistance . Generate Biomedicines ; 2024 . Available from: https://cdn.generatebiomedicines.com/team/IDWeek-2024_Preclinical-100924.pdf [Last accessed: May 13 , 25
15.First-in-human study of a novel half life extended monoclonal antibody (GB-0669) against SARS-CoV-2 and related sarbecoviruses . Generate : Biomedicines; 2024 . Available from: https://cdn.generatebiomedicines.com/team/IDWeek-2024-FTIH-presentation-100924.pdf [Last accessed: May 13 , 25